Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.34 |
| ▸ | ITGAV | P06756 | 3/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.34 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.34 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | POLQ | O75417 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 3/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GPR6 | P46095 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884480 | 0.95 | WDR5 (0.34) | RIPK3SLC22A12ARPOLQWDR5 | |
| SCHEMBL21884400 | 0.93 | CSNK2A1 (0.35) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL21884369 | 0.88 | WDR5 (0.36) | RIPK3SLC22A12ARATRWDR5 | |
| SCHEMBL21884425 | 0.86 | ITGB3 (0.35) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL21884579 | 0.84 | ITGB3 (0.32) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL21884465 | 0.84 | AR (0.33) | RIPK3SLC22A12POLBARPOLQ | |
| SCHEMBL21884359 | 0.84 | RIPK3 (0.32) | RIPK3SLC22A12POLBARPOLQ | |
| SCHEMBL21884660 | 0.84 | CCNT1 (0.40) | — | |
| SCHEMBL24066342 | 0.84 | PGR (0.39) | POLBARWDR5 | |
| SCHEMBL21884616 | 0.83 | WDR5 (0.40) | ITGB3ITGAVITGA2BITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | ITGB3 4264/4885ITGAV 3704/4885ITGA2B 3898/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | ITGB3 3532/4885ITGAV 3045/4885ITGA2B 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.